TuHURA Biosciences Inc (HURA)
🔔 Watch stock
symbol.quality_heading
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
The going-concern qualification for 2025 and the nearly empty till ($3.6 million) are hard warning signals, as are Altman-Z deep in the red, Piotroski 3 of 9 and three insolvency scanners. At the same time the insider credit facility has defused the acute distress (runway "through the end of 2028") — at distress rates, with a pledge of assets and a perpetual royalty. The case is binary: an IFx-2.0 approval could lever the slim market value upward, a failure hits a company that has pledged its entire assets. The decision is yours.
symbol.quality_note
TuHURA Biosciences is building a cancer immunotherapy that makes tumors look to the immune system like bacteria — a fascinating idea now being tested in Phase 3 against rare Merkel cell skin cancer. Only, at the turn of the year the company had just $3.6 million left in the till, and the auditor wrote a going-concern qualification into its opinion. We read the annual report (10-K) for 2025 and the quarterly report (10-Q) as of March 31, 2026: not a cent of revenue, $141 million in accumulated losses — and a rescue in April 2026 that comes from a company attributable to the major shareholder, at 12 percent interest, secured against everything, including a perpetual royalty on the lead drug. Not investment advice — just a cash count before you bet on the all-clear.
Read the analysis
Stock Watch
This analysis is as of July 15, 2026. Stock Watch will tell you what's changed at HURA since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.20 $ — 62% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 14.07.2026 gegen die Geschäftsberichte (10-K) für die Geschäftsjahre 2025 (eingereicht 31.03.2026) und 2024 (31.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 31.03.2026. TuHURA Biosciences ist ein immunonkologisches Unternehmen in der klinischen Phase (Multi-Indikations-Immunmodulator-Plattform ImmuneFx; Leitwirkstoff IFx-2.0, ein Innate-Immune-Agonist, gegen Merkelzellkarzinom als Zusatztherapie zu Pembrolizumab). In sämtlichen ausgewerteten SEC-Filings kommen die Begriffe „artificial intelligence“ und „machine learning“ kein einziges Mal vor (Trefferzahl 0 in 10-K 2025, 10-K 2024 und den 10-Qs). Es gibt keine KI-Produkte oder -Dienste als Umsatzquelle (das Unternehmen erzielt überhaupt keinen Produktumsatz), keinen dokumentierten operativen KI-Einsatz — etwa in der Wirkstoff-Forschung — und kein konkretes KI-Geschäftsrisiko für das eigene Modell. Die Technologie ist ausschließlich biologisch (Zell- und Gentherapien, pDNA-basierte innate-immune-Agonisten, bispezifische Antikörper-Wirkstoff-Konjugate gegen MDSCs). Damit bleibt es beim dokumentierten Negativ-Befund „neutral“: kein wesentlicher KI-Bezug in den Pflichtdokumenten.
View the full file — quotes, sources, reviewed filings
„We employ a multi-indication immunomodulator platform (ImmuneFx) that utilizes both cell and gene therapies, together, to stimulate the immune system to recognize and combat tumor cells."
Wir setzen eine Multi-Indikations-Immunmodulator-Plattform (ImmuneFx) ein, die sowohl Zell- als auch Gentherapien nutzt, um das Immunsystem dazu zu bringen, Tumorzellen zu erkennen und zu bekämpfen.
„IFx-2.0 innate immune agonist, our lead product candidate, is comparatively simple to administer and involves only the injection into a patient's tumor, or lymph node, of a relatively small amount of pDNA that is designed to encode for an immunogenic gram positive bacterial protein that gets expressed on the surface of the patient's tumor so that the surface of the tumor looks like a bacterium."
IFx-2.0, unser wichtigster Wirkstoffkandidat und ein Innate-Immune-Agonist, ist vergleichsweise einfach zu verabreichen und erfordert nur die Injektion einer relativ kleinen Menge pDNA in den Tumor oder Lymphknoten eines Patienten; diese pDNA ist so konstruiert, dass sie ein immunogenes Eiweiß eines grampositiven Bakteriums codiert, das auf der Tumoroberfläche ausgeprägt wird, sodass der Tumor für das Immunsystem wie ein Bakterium aussieht.
Filings Reviewed: 10-Q 2026-05-15 · 10-Q 2025-11-14 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2026-03-31 · 10-K 2025-03-31
Rated on July 14, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 265.5% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | – | – | – | – | -3 | -3 |
| 2025: Q1 | -0.10 | – | 0 | – | – | -5 | -5 |
| 2025: Q2 | -0.15 | – | 0 | – | – | -6 | -6 |
| 2025: Q3 | -0.11 | – | 0 | – | – | -11 | -11 |
| 2025: Q4 | -0.11 | – | 0 | – | – | -6 | -6 |
| 2026: Q1 | -0.12 | – | 0 | – | – | -4 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
The ImmuneFx idea is fascinating: IFx-2.0 makes tumors look to the immune system like bacteria. For the lead candidate there is an unusually clear regulatory path — a Phase 3 trial agreed with the FDA (Special Protocol Assessment) in Merkel cell carcinoma via the accelerated approval pathway, Phase 3 since June 2025 (annual report 10-K 2025).
The auditor gave the 10-K 2025 a going-concern qualification; cash stood at only $3.6 million as of December 31, 2025, against $27.6 million of annual cash outflow. The $50 million credit facility of April 2026 defuses the acute distress (runway per the 10-Q "through the end of 2028"), but presupposes the facility can be drawn.
The credit facility comes from an insider (Parkview/K&V, an entity owned by major shareholder Vijay Patel, stake over 5%): 12% interest (plus 6% on default), secured by virtually all assets, including a 75-percent profit sweep and a perpetual royalty on future IFx-2.0 revenue. A rescue that secures survival and at the same time makes it more expensive.
No product revenue since inception; net loss up from $21.7 to $30.1 million, accumulated deficit $141.2 million. The share count multiplied within a year from 12.2 to 63.6 million — ongoing, heavy dilution, most recently intensified by the Kineta acquisition.
Plus 178 percent in six months and plus 532 percent above the 52-week low, carried by approval and rescue hope; technical scanners read the rally as a top formation (Weinstein Stage 3). Only about 15 percent institutional and about 35 percent insider ownership — a thinly traded micro-cap paper with a binary outcome.
TuHURA is not a case of substance versus story, but a pure bet with clear conditions: a fascinating cancer technology with a clear Phase 3 path on one side — on the other an auditor who doubted the company could survive for 2025, not a cent of revenue, $141 million in accumulated losses and a rescue that comes from a major shareholder: $50 million at 12 percent, secured against everything, including a perpetual royalty on the lead drug. The acute bankruptcy danger is defused — the price for it is a new, expensive clock that ticks. Not investment advice.
- TuHURA emerged in October 2024 from the reverse merger with Kintara Therapeutics (1-for-35 reverse stock split, name change from KTRA to HURA); price and share history before October 2024 belong to the predecessor shell. The 2013 IPO year listed in databases refers to this shell.
- The disappearance of the going-concern qualification in the 10-Q as of March 31, 2026 rests on the $50 million credit facility agreed only after the 10-K (April 2026); its runway "through the end of 2028" presupposes, per the report, that the facility can be drawn.
- Price, valuation and scanner figures dated to July 8, 2026 (about $2.60); analyses are evergreen, daily prices are not a buy argument.
About the Company
TuHURA Biosciences, Inc., ein immunonkologisches Unternehmen in der klinischen Phase, entwickelt neuartige Technologien zur Behandlung mit Krebsimmuntherapien.
| Employees | 22 |
|---|---|
| Headquarters | Tampa, FL |
| Website | tuhurabio.com |
| IPO Date | 22. Feb 2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| James A. Bianco M.D. | President, CEO & Director | 1957 |
| Michael Lawman | Co-Founder | – |
| Patricia Lawman | Co-Founder | – |
| Michael Krsulich | Head of Quality Assurance | – |
| Amanda Garofalo | Senior Vice President of Clinical Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.